Chronic inflammation and cancer.
A substantial body of evidence supports the conclusion that chronic inflammation can predispose an individual to cancer, as demonstrated by the association between chronic inflammatory bowel diseases and the increased risk of colon carcinoma. Chronic inflammation is caused by a variety of factors, including bacterial, viral, and parasitic infections, chemical irritants, and nondigestible particles. The longer the inflammation persists, the higher the risk of associated carcinogenesis. This review describes some of the underlying causes of the association between chronic inflammation and cancer. Inflammatory mediators contribute to neoplasia by inducing proneoplastic mutations, adaptive responses, resistance to apoptosis, and environmental changes such as stimulation of angiogenesis. All these changes confer a survival advantage to a susceptible cell. In this article, we discuss the contribution of reactive oxygen and nitrogen intermediates, prostaglandins, and inflammatory cytokines to carcinogenesis. A thorough understanding of the molecular basis of inflammation-associated neoplasia and progression can lead to novel approaches to the prevention and treatment of cancer.
Shacter
Emily
E
Laboratory of Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892-4555, USA. shacter@cber.fda.gov
Weitzman
Sigmund A
SA
D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage; D002908:Chronic Disease; D016207:Cytokines / Q000502:physiology; D004198:Disease Susceptibility; D006801:Humans; D007239:Infections / Q000150:complications; D007249:Inflammation / Q000150:complications* / Q000503:physiopathology; D018836:Inflammation Mediators / Q000502:physiology; D009369:Neoplasms / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control
D000975:Antioxidants; D016207:Cytokines; D018836:Inflammation Mediators